Research
Hormonal
Non-optimal systolic blood pressure (SBP) is the leading metabolic risk factor for cardiometabolic mortality in the MENA region, causing 48% of deaths.
Monitor and manage blood pressure aggressively, as it is the number one metabolic driver of heart disease and diabetes deaths in the MENA region. Target levels below 115 mm Hg for optimal protection.
GoodSupportsHIGH confidence
Non-optimal SBP (>115 mm Hg) was the leading metabolic risk for CMD mortality in the region accounting for 48% of CMD deaths (436 190 deaths...)
Why this rating
Based on large cohort pooling projects and systematic reviews.
Source
The impact of dietary habits and metabolic risk factors on cardiovascular and diabetes mortality in countries of the Middle East and North Africa in 2010: a comparative risk assessment analysis
Ashkan Afshin et al. · BMJ Open · 2015
DOI 10.1136/bmjopen-2014-006385
cohortCited 128×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Suboptimal diet is the leading risk factor for cardiometabolic disease mortality in the Middle East and North Africa, accounting for 48% to 72% of deaths depending on the country.Good
- Low intake of fruits and whole grains are the two most significant individual dietary risk factors for cardiometabolic mortality in the MENA region, accounting for 12% and 11% of deaths respectively.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →